Critics have excoriated Sarepta Therapeutics (SRPT) for winning FDA approval for a drug to treat Duchenne muscular dystrophy despite scant scientific proof that it helps patients suffering from the inherited, muscle-wasting disease.

Sarepta has long insisted the doubters are wrong. And on Wednesday, the biotech firm strengthened its case with data from a new clinical trial: A second Sarepta drug, designed to treat another form of Duchenne muscular dystrophy, is producing significantly larger quantities of dystrophin, a crucial muscle protein normally missing in these patients.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy